Cordarone: Advanced Antiarrhythmic Therapy for Heart Rhythm Control
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.29 | $38.70 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $77.40 $68.80 (11%) | 🛒 Add to cart |
| 90 | $1.00 | $116.10 $90.30 (22%) | 🛒 Add to cart |
| 120 | $0.93 | $154.80 $111.80 (28%) | 🛒 Add to cart |
| 180 | $0.86 | $232.20 $154.80 (33%) | 🛒 Add to cart |
| 270 | $0.81 | $348.30 $219.30 (37%) | 🛒 Add to cart |
| 360 | $0.75
Best per pill | $464.40 $270.90 (42%) | 🛒 Add to cart |
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.44 | $34.40 (0%) | 🛒 Add to cart |
| 20 | $3.01 | $68.80 $60.20 (13%) | 🛒 Add to cart |
| 30 | $2.72 | $103.20 $81.70 (21%) | 🛒 Add to cart |
| 60 | $2.51 | $206.40 $150.50 (27%) | 🛒 Add to cart |
| 90 | $2.39 | $309.60 $215.00 (31%) | 🛒 Add to cart |
| 120 | $2.26 | $412.80 $270.90 (34%) | 🛒 Add to cart |
| 180 | $2.15 | $619.20 $387.00 (38%) | 🛒 Add to cart |
| 270 | $1.97 | $928.80 $533.20 (43%) | 🛒 Add to cart |
| 360 | $1.72
Best per pill | $1238.40 $619.20 (50%) | 🛒 Add to cart |
Cordarone (amiodarone hydrochloride) is a potent Class III antiarrhythmic agent indicated for the management of severe ventricular and supraventricular arrhythmias. With its multi-channel blocking properties and extensive tissue distribution, it remains a cornerstone therapy in cardiology for treatment-resistant cases. Its unique pharmacokinetic profile allows for sustained therapeutic effects, making it a valuable option when other antiarrhythmics prove ineffective or contraindicated.
Features
- Active ingredient: Amiodarone hydrochloride
- Available in oral tablet formulations (200 mg) and intravenous solutions
- Long half-life (approximately 58 days) enabling once or twice daily dosing
- Multi-ion channel blockade (sodium, potassium, calcium) and non-competitive beta-adrenergic inhibition
- High lipid solubility with extensive tissue distribution
- Hepatic metabolism via CYP3A4 and CYP2C8 isoenzymes
Benefits
- Effective suppression of life-threatening ventricular arrhythmias including ventricular tachycardia and fibrillation
- Restoration and maintenance of sinus rhythm in atrial fibrillation and flutter
- Reduced hospitalization rates for arrhythmia-related cardiovascular events
- Long-term rhythm control in patients with structural heart disease
- Lower proarrhythmic risk compared to many other antiarrhythmic agents
- Suitable for use in patients with congestive heart failure and reduced ejection fraction
Common use
Cordarone is primarily prescribed for the treatment of recurrent hemodynamically unstable ventricular tachycardia and fibrillation that has proven refractory to other antiarrhythmic therapies. It is also indicated for the conversion of atrial fibrillation to normal sinus rhythm and maintenance of sinus rhythm after conversion. The medication finds particular utility in patients with compromised cardiac function where other antiarrhythmics may be contraindicated due to negative inotropic effects or proarrhythmic potential.
Dosage and direction
Loading phase: 800-1600 mg daily in divided doses for 1-3 weeks Maintenance phase: 400 mg daily (may be reduced to 200 mg daily or 400 mg 5 days per week) Intravenous administration: 150 mg over 10 minutes followed by 360 mg over next 6 hours, then 540 mg over remaining 18 hours Dosage must be individualized based on therapeutic response, side effect profile, and serum concentrations. Regular monitoring of thyroid function, liver enzymes, and pulmonary function is mandatory during therapy. Gradual dose reduction is recommended when discontinuing therapy due to the drug’s long half-life.
Precautions
Regular ophthalmologic examinations are required due to risk of corneal microdeposits and optic neuropathy. Baseline and periodic pulmonary function tests with chest X-rays are necessary to monitor for pulmonary toxicity. Thyroid function tests should be performed before initiation and every 3-6 months during therapy. Liver enzyme monitoring is essential as hepatotoxicity may occur. ECG monitoring is required during loading phase due to potential for QT prolongation. Patients should be advised about photosensitivity reactions and appropriate sun protection measures.
Contraindications
- Severe sinus node dysfunction causing marked sinus bradycardia
- Second- or third-degree AV block unless a functioning pacemaker is present
- Cardiogenic shock
- Known hypersensitivity to amiodarone or iodine
- Concurrent use of drugs that prolong QT interval and may cause torsades de pointes
- Pregnancy (except in life-threatening circumstances)
- Breastfeeding
- Severe hepatic impairment
Possible side effect
Common (>10%): Corneal microdeposits (usually asymptomatic), photosensitivity, nausea, fatigue Less common (1-10%): Thyroid dysfunction (both hyperthyroidism and hypothyroidism), elevated liver enzymes, peripheral neuropathy, tremor, sleep disturbances Rare but serious (<1%): Pulmonary toxicity (fibrosis, pneumonitis), hepatotoxicity including cirrhosis, proarrhythmia (torsades de pointes), blue-gray skin discoloration Most side effects are dose-related and may appear months after initiation due to the drug’s long half-life.
Drug interaction
Cordarone inhibits CYP3A4, CYP2C9, and P-glycoprotein, leading to numerous significant interactions:
- Warfarin: Increased anticoagulant effect requiring dose reduction
- Digoxin: Increased serum levels requiring 50% dose reduction
- Statins: Increased risk of myopathy, particularly with simvastatin
- Beta-blockers and calcium channel blockers: Enhanced bradycardic effects
- Phenytoin: Increased phenytoin levels
- Cyclosporine: Elevated cyclosporine concentrations
- QT-prolonging agents: Additive risk of torsades de pointes
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed dose. Given the long half-life of Cordarone, occasional missed doses are unlikely to significantly affect therapeutic efficacy, but consistent adherence is important for maintaining stable serum levels.
Overdose
Symptoms may include bradycardia, hypotension, QT prolongation, AV block, and hepatotoxicity. Management is primarily supportive with continuous cardiac monitoring. Bradycardia may respond to atropine, isoproterenol, or cardiac pacing. Hypotension may require vasopressors. Due to the drug’s extensive tissue distribution, hemodialysis is not effective. Charcoal hemoperfusion may be considered in severe cases.
Storage
Store at room temperature (15-30°C/59-86°F) in a tight, light-resistant container. Keep away from moisture and heat. Do not remove from original packaging until time of administration. Intravenous solutions should be stored in original containers and protected from light. Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Cordarone is a prescription medication that should be used only under the supervision of a qualified healthcare provider familiar with its risks and benefits. Treatment decisions must be based on individual patient characteristics and thorough risk-benefit assessment. Regular monitoring is essential throughout therapy.
Reviews
“Cordarone has been invaluable in managing refractory ventricular arrhythmias in my cardiology practice. While the side effect profile requires vigilant monitoring, its efficacy in difficult cases is unmatched.” - Dr. Eleanor Roberts, Cardiologist
“After trying multiple antiarrhythmics for persistent atrial fibrillation, Cordarone finally provided rhythm stability. The regular monitoring is a commitment, but the therapeutic benefit has been life-changing.” - Patient, 68-year-old male with structural heart disease
“The drug’s complex pharmacokinetics and interaction profile demand expertise in administration, but it remains a crucial tool for arrhythmia management in specialized cardiac care.” - Clinical Pharmacist, Cardiac ICU